Media Summary: ICANS is one of CAR T-cell therapy's most challenging toxicities, posing a considerable risk to patients 5th webinar in a series of 6 entitled Best Practices for Integrating Patient-Reported Outcomes (PROs) in The full article for this interview is available on
Using Oncology Data To Prevent - Detailed Analysis & Overview
ICANS is one of CAR T-cell therapy's most challenging toxicities, posing a considerable risk to patients 5th webinar in a series of 6 entitled Best Practices for Integrating Patient-Reported Outcomes (PROs) in The full article for this interview is available on Speaker: Charles Fuchs, MD, MPH Richard Sackler & Jonathan Sackler Professor of Medicine (Medical October 24, 2017: Charles S. Fuchs, MD, MPH. Welcome back to Only Oncologists in the Building — the podcast where real oncologists cut through the hype, the myths, and ...
Audio described version: The “real world” evidence that observational Dr. Lillian Siu recently co-led a study published in Nature Medicine highlighting the potential of 'big
